Replimune

Yahoo Finance • 16 hours ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”)(NASDAQ: REPL). Such investors are advised to contact Danielle Pey... Full story

Yahoo Finance • 2 days ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusi... Full story

Yahoo Finance • 2 days ago

Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm

NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (NASDA... Full story

Yahoo Finance • 3 days ago

Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - Hagens Berman

SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks to represent investors who purchased or otherwise a... Full story

Yahoo Finance • 3 days ago

Replimune Group’s SWOT analysis: oncology biotech stock faces FDA hurdles

Replimune Group Inc (NASDAQ:REPL), a biotechnology company focused on developing novel oncolytic immunotherapies for cancer treatment, has been navigating a complex landscape of clinical trials, regulatory challenges, and market expectatio... Full story

Yahoo Finance • 3 days ago

REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit... Full story

Yahoo Finance • 3 days ago

REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Replimune Group, Inc. (“Repli... Full story

Yahoo Finance • 4 days ago

Class Action Announcement for Replimune Group, Inc. (REPL): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Replimune Group, Inc.

RADNOR, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Replimune Group, Inc. (“Replimune”) (NASDAQ:... Full story

Yahoo Finance • 4 days ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusi... Full story

Yahoo Finance • 4 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged... Full story

Yahoo Finance • 4 days ago

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchased the securities of Replimune Group, I... Full story

Yahoo Finance • 5 days ago

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group (REPL) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm 

ATLANTA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or mi... Full story

Yahoo Finance • 6 days ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Replimune between Nov... Full story

Yahoo Finance • 6 days ago

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Replimune Group, Inc. (REPL) Shareholders

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit... Full story

Yahoo Finance • 7 days ago

Biotech sector slips amid reported return of ousted FDA official

[FDA headquarters in Washington DC.] JHVEPhoto/iStock Editorial via Getty Images Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad w... Full story

Yahoo Finance • 7 days ago

Jefferies lowers Replimune Group stock price target to $8 from $10

Investing.com - Jefferies has reduced its price target on Replimune Group (NASDAQ:REPL) to $8.00 from $10.00 while maintaining a Buy rating on the stock. The new target represents the high end of analyst expectations, with targets ranging... Full story

Yahoo Finance • 9 days ago

Shareholders of Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL

NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit... Full story

Yahoo Finance • 10 days ago

Replimune Group, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights – REPL

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged... Full story

Yahoo Finance • 12 days ago

Replimune Group, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit... Full story

Yahoo Finance • 13 days ago

REPL DEADLINE: Replimune Group Investors Should Contact Block & Leviton By September 22nd To Join Securities Fraud Lawsuit

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Block & Leviton reminds investors that a securities fraud lawsuit has been filed against Replimune Group, Inc. (Nasdaq: REPL) and certain of its executives. Investors who have lost money in their... Full story